MedTrace Logo

Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane

NCT00291798 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2006-09-19

No results posted yet for this study

Summary

The objective of the present clinical investigation is to determine whether hormonal therapy given preoperatively is able to reduce tumor size to an extent that facilitates breast-conserving procedures.

Conditions

Interventions

PROCEDURE

rate of remission

Sponsors & Collaborators

  • Pharmacia Austria GmbH

    collaborator UNKNOWN

  • Austrian Breast & Colorectal Cancer Study Group

    lead NETWORK

Principal Investigators

  • Brigitte Mlineritsch, MD · Austrian Breast & Colorectal Cancer Study Group

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
59 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-09-30
Completion
2009-03-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00291798 on ClinicalTrials.gov